^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Delito (rituximab biosimilar)

    i
    Other names: TQB2303, TQB 2303
    Company:
    Sino Biopharm
    Drug class:
    CD20 inhibitor
    Related drugs:
    4years
    Rituximab, Pembrolizumab, and Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
    N=37 --> 62
    Clinical • Enrollment change • PD(L)-1 Biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Keytruda (pembrolizumab) • Rituxan (rituximab) • Gazyva (obinutuzumab) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar)
    4years
    Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma (clinicaltrials.gov)
    P2; N=45; Not yet recruiting; Sponsor:Academic and Community Cancer Research United
    New P2 trial • Clinical
    |
    CD34 (CD34 molecule)
    |
    clonoSEQ
    |
    Rituxan (rituximab) • cytarabine • bortezomib • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib) • daunorubicin • Rituxan Hycela (rituximab/hyaluronidase) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar)
    4years
    Rituximab, Pembrolizumab, and Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
    Trial completion date: Feb 2021 --> Feb 2023 | Trial primary completion date: Feb 2021 --> Feb 2023
    Clinical • Trial completion date • Trial primary completion date • PD(L)-1 Biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Keytruda (pembrolizumab) • Rituxan (rituximab) • Gazyva (obinutuzumab) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar)
    5years
    A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov)
    P2; Not yet recruiting --> Recruiting
    Enrollment open • Clinical
    |
    CCND1 (Cyclin D1) • CD34 (CD34 molecule)
    |
    CCND1 expression
    |
    clonoSEQ
    |
    Rituxan (rituximab) • cytarabine • Calquence (acalabrutinib) • bendamustine • Belrapzo (bendamustine RTD) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar)
    5years
    A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov)
    P2; N=369; Not yet recruiting; Sponsor:ECOG-ACRIN Cancer Research Group
    New P2 trial • Clinical
    |
    CCND1 (Cyclin D1) • CD34 (CD34 molecule)
    |
    CCND1 expression
    |
    clonoSEQ
    |
    Rituxan (rituximab) • cytarabine • Calquence (acalabrutinib) • bendamustine • Belrapzo (bendamustine RTD) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar)